Showing 41-50 of 127 results for "".
Journal Club: S. Aureus-Driven AD Exacerbation
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-s-aureus-driven-ad-exacerbation/32404/Practical Dermatology Editorial Board member Christopher Bunick, MD, FAAD, discusses a recent Journal of Drugs in Dermatology article about the need for a novel treatment for S. aureus exacerbated atopic dermatitis with Adelaide Hebert, MD.Schachner LA, Andriessen A, Gonzalez ME, Lal K, Hebert AA, EJournal Club: Tapinarof Cream in Pediatric Patients
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-tapinarof-cream-in-pediatric-patients/32399/Practical Dermatology Editorial Board member Peter Lio, MD, speaks with Mona Shahriari, MD, about the Journal of Dermatology article "A phase 2, randomized, double-blind, vehicle-controlled trial of tapinarof cream in Japanese pediatric patients with atopic dermatitis," and the general importance ofDr. Goldberg Discusses Experience with the VariLite Laser
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-goldberg-discusses-experience-with-gemini-laser/19468/“One of the great things about being in the laser field is there are new lasers that come out every day. It makes it a very exciting arena to be in. The problem is the popular machine of today, unfortunately, often becomes the machine that you don't need a year from now. The VariLite is tried andAnalyzing Safety Data From Level Up
https://practicaldermatology.com/series/the-practical-dermatology-podcast/analyzing-safety-data-from-level-up/33944/The latest news and updates, plus Matthew Zirwas, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the importance of the Week 16 safety data from the Level Up study on upadacitinib. Silverberg JI, Bunick CG, et al. Efficacy and safety of upadacitinib versu- J&J Seeks FDA Approval for Pediatric Tremfya Indicationshttps://practicaldermatology.com/news/jj-seeks-fda-approval-pediatric-tremfya-indications/2468706/Johnson & Johnson (J&J) has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Tremfya (guselkumab), seeking approval for pediatric indications. Tremfya, the first approved monoclonal antibody IL-23 inhibitor that select
- J&J Expands Atopic Dermatitis Pipeline with Yellow Jersey Therapeutics Acquisitionhttps://practicaldermatology.com/news/jj-expands-ad-pipeline-yellow-jersey-therapeutics-125-billion-acquisition/2463207/Johnson & Johnson (J&J) has announced its plan to acquire Yellow Jersey Therapeutics (a subsidiary of Numab Therapeutics) for $1.25 billion in cash, according to a news release. The acquisition includes the bispecific antibody NM26, which is currently advancing to phase 2 studies f
- Cynosure to Name Stephen J. Webber as New CFOhttps://practicaldermatology.com/news/cynosure-to-name-stephen-j-webber-as-new-cfo/2458436/Cynosure, Inc. announced that Stephen J. Webber will join the company on October 10, 2016 as Executive Vice President. Mr. Webber will then become Chief Financial Officer and Chief Accounting Officer effective upon the filing in Novembe
- ASLMS to Honor David J. Cuccia, PhDhttps://practicaldermatology.com/news/20120314-aslms_to_honor_david_j_cuccia_phd/2459844/David J. Cuccia, Ph.D, Chief Technology Officer and CEO at Modulated Imaging, Inc. Irvine, California, will receive the 2012 Dr. Horace Furumoto Innovations Professional Development Grant at the Annual Conference of the American Society for Laser Medicine and Surgery
- Gryphon Acquires Roc Skincare from J & Jhttps://practicaldermatology.com/news/gryphon-acquires-roc-skincare-from-j-j/2459930/Gryphon Investors has acquired RoC Skincare from Johnson & Johnson Consumer, Inc. The transaction is Gryphon's second investment in the beauty sector after the firm acquired indie color cosmet
- YCANTH Receives Permanent J-Code Status from CMShttps://practicaldermatology.com/news/ycanth-receives-permanent-j-code-from-cms/2462230/The Centers for Medicare and Medicaid Services (CMS) have granted a permanent J-code (J7354) for YCANTH, the only FDA-approved treatment for molluscum contagiosum.